June 1, 2020 07:10 AM EDTUpdated 09:48 AM
Coronavirus

Covid-19 roundup: Did in­sid­ers cash in on pos­i­tive news re­port about Gilead be­fore pub­li­ca­tion?

Amber Tong

A se­ries of bull­ish trades on Gilead op­tions just be­fore the re­lease of a fa­vor­able news sto­ry is rais­ing ques­tions among reg­u­la­to­ry ex­perts, Reuters …

Endpoints News

Sign up to read this article for free.

Get free access to a limited number of articles, plus choose newsletters to get straight to your inbox.

BECOME A PREMIUM SUBSCRIBER
TRENDING NOW

PTC re­ports Phase 2 ALS fail, sells pri­or­i­ty re­view vouch­er for $150M

Nor­bert Bischof­berg­er's time as Kro­nos CEO ends as biotech seeks new life

To lead NIH, Trump taps Stan­ford aca­d­e­m­ic and pan­dem­ic re­sponse crit­ic Jay Bhat­tacharya

No­var­tis to cut 139 jobs in NJ as part of com­mer­cial re­fo­cus

Re­cur­sion re­duces work­force; Ox­ford Nanopore teams up with UK Biobank

Ad­vanz Phar­ma faces re­vo­ca­tion of Eu­ro­pean au­tho­riza­tion for liv­er dis­ease drug Ocali­va

A service from the Financial Times